HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors

AIDS

Volumn 12, Issue 15, 1998, Pages 1991-1997

  Staszewski, Schlomo ^a,d   DeMasi, Ralph ^b   Hill, Andrew M ^c   Dawson, Debra ^b  

^a GOETHE UNIVERSITY   (Germany)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

CD4 count; Clinical progression; HIV RNA

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; EUROPE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NORTH AMERICA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 0032558794     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199815000-00010     Document Type: Article

References (24)

1. Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997, 126:946-954.
2. Craib KJP, Strathdee SA, Hogg RS, et al.: Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection. J Inf Dis. 1997, 176:798-800.
3. O'Brien WA, Hartigan PM, Martin D, et al.: The relationship of treatment induced changes in plasma HIV-1 RNA and CD4 lymphocyte count to progression to AIDS in the Department of Veteran Affairs study group Zidovudine study. N Engl J Med. 1996, 334: 426-431.
4. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med. 1996, 335:1091-1098.
5. Carpenter CJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS society - USA panel. JAMA. 1997, 277:1962-1969.
6. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200-500 CD4 cells per cubic millimeter. N Engl J Med. 1995, 333:1662-1669.
7. Bartlett JA, Benoit SL, Johnson VA, et al.: Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Ann Intern Med. 1996, 125:161-172.
8. Katlama C, Ingrand D, Loveday C, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in antitretroviral-naive patients. JAMA. 1996, 276:118-125.
9. Staszewski S, Loveday C, Picazo JJ, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. JAMA. 1996, 276:111-117.
10. CAESAR coordinating committee: Randomised trial of the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997, 349:1413-1421.
11. Rozenbaum W, on behalf of the AVANTI study group. AVANTI-1: A randomised double blind comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV-1 infection: ZDV/3TC vs ZDV/3TC/loviride in anti-retroviral naive patients. Fourth Conference on Retroviruses and Opportunistic Infections, Washington DC, USA, January 1997 [Abstract 368]
12. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41(RR-17):1-19.
13. Montaner JSG, Raboud JM, Rae S, et al.: Full suppression of viral replication to below 20 copies/ml is needed to achieve a durable antiviral response. Sixth European Conference on Clinical Aspects and Treatment of HIV-infection. Hamburg October 1997 [Abstract number 105].
14. Feinberg M: Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997, 349:1408-1409.
15. Miller V, Staszewski S, Boucher CAB, Phair JP: Clinical experience with non-nucleoside reverse transcriptase inhibitors. AIDS 1997, (suppl A): S157-S164.
16. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995, 374:569-571.
17. Cao Q, Gu Z, Parniak MA, et al.: The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother. 1993, 37:1390-1392.
18. Opravil M, DeMasi R, Hill A, Dawson D: Baseline HIV RNA determines the durability of RNA suppression during AZT/3TC treatment. International Congress on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [Abstract 1-130].
19. Yu G, Chang Y, Greenberg MS, Clendennin NJ: Durability of virological response in patients treated with viracept (nelfinavir) in combination with zidovudine and lamivudine. Sixth European conference on clinical aspects and treatment of HIV-infection. Hamburg October 1997 [Abstract number 410].
20. Goebel F, on behalf of the AVANTI study group: AVANTI-2. A randomised, double-blind, comparative trial to evaluate combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC versus AZT/3TC/indinavir in anti-retroviral naive patients. Sixth European Conference on Clinical Aspects and Treatment of HIV-infection. Hamburg October 1997 [Abstract number 211].
21. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997, 337:725-733.
22. Loveday C, Devereux H, Burke A, et al.: Variability in plasma HIV-1 quantification using four different commercial assays, in patients with non-clade B virus, prior-to antiretroviral therapy. Sixth European Conference on Clinical Aspects and Treatment of HIV-infection. Hamburg October 1997 [Abstract number 907].
23. Hughes MD, Stein DS, Gundacker HM, et al.: Within subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Inf Dis. 1994, 169:28-36.
24. DeMasi R, Bartlett J: What rises or reductions in HIV-1 RNA are clinically significant? Sixth European Conference on Clinical Aspects and Treatment of HIV-infection. Hamburg October 1997 [Abstract number 102].